<DOC>
	<DOCNO>NCT02352675</DOCNO>
	<brief_summary>Lysine analog , like tranexamic acid ( TXA ) epsilon aminocaproic acid ( EACA ) , antifibrinolytic agent routinely administer child undergo different surgery associate high bleeding risk ( e.g . cardiac , craniofacial , orthopedic surgery ) . Although grow literature regard pharmacokinetic characteristic drug child , plasmatic concentration require completely inhibit fibrinolysis remain determined . In vitro study , investigator use experimental model fibrinolysis design rotational thromboelastometry ( ROTEM® ) determine minimal concentration inhibit fibrinolysis TXA EACA . In addition , study use create validate new experimental assay measure fibrinolysis effect antifibrinolytic agent .</brief_summary>
	<brief_title>Determination Minimal Concentration Antifibrinolytics Required Inhibit t-PA-activated Fibrinolysis</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<criteria>infant 2 month age equal le 12 month age weigh 5.0 kg either CHD schedule undergo elective cardiac catheterization lab procedure CHD schedule undergo noncardiac surgery ( craniofacial surgery , neurosurgery , orthopedic surgery ) operating room undergo emergent procedure , child moribund condition ( American Society Anesthesiology ( ASA 5 ) child hematological and/or oncological disease Jehovah witness child preoperative coagulopathy , define platelet count &lt; 100,000/μL , fibrinogen level &lt; 100 mg/dL , prothrombin time ( PT ) activate partial thromboplastin time ( PTT ) &gt; 1.5 normal range</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>